Drug profile · INN
insulin aspart recombinant
NOVOLOG PENFILL
- US status
- approved
- Patents linked
- 0
- News articles
- 0
Quick answer
insulin aspart recombinant (NOVOLOG PENFILL) is an FDA-listed pharmaceutical active ingredient. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
INN insulin aspart recombinant
Brand NOVOLOG PENFILL
Route SUBCUTANEOUS
Formulation INJECTABLE
Frequently asked questions
What is insulin aspart recombinant?
insulin aspart recombinant (NOVOLOG PENFILL) is an FDA-listed pharmaceutical active ingredient. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for insulin aspart recombinant?
NOVOLOG PENFILL is a marketed brand name for insulin aspart recombinant. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of insulin aspart recombinant?
insulin aspart recombinant has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.